INTRODUCTION {#S1}
============

Type 2 diabetes mellitus (T2DM) is featured by insulin-independently elevated levels of blood glucose, *i.e.* hyperglycemia. Hyperglycemia is a high risk factor for the development of non-alcoholic steatohepatitis (NASH) ([@R1]), which is an understudied complication of T2DM. Approximately 15--40% of NASH patients develop hepatic fibrosis ([@R2]). Hyperglycemia facilitates the non-enzymatic formation of [a]{.ul}dvanced [g]{.ul}lycation [e]{.ul}nd-products (AGEs), which are a heterogeneous group of molecules formed by non-oxidative and oxidative reactions of sugars with proteins and/or lipids ([@R3]). AGEs accumulate in tissues and circulation during aging, as well as diabetic, chronic renal failure and liver fibrogenesis ([@R4]), leading to inflammation and pathogenesis ([@R5]). Effects of AGEs are mediated by their receptor system, which could be generally divided into two categories. [Receptor for AGEs]{.ul} (RAGE) facilitates oxidative stress (OS), cell growth, and inflammation ([@R6]). [AGE receptors]{.ul} (AGE-Rs), *e.g.* AGE-R1 (also called OST-48), are responsible for detoxification and clearance of AGEs ([@R7]). In contrast to a dramatic increase in expression of RAGE in diabetes with high levels of AGEs ([@R8]), the abundance of AGE-R1 is significantly reduced in diabetic organs, *e.g.* kidney ([@R9]), suggesting a possible inverse relationship between AGEs-mediated cell injury and low expression of AGE-R1. In addition to its participation in AGE removal, AGE-R1 negatively regulates AGE pro-inflammatory signal processing ([@R7]).

Hepatic stellate cells (HSCs) are the major effectors during hepatic fibrogenesis ([@R10]). During hepatic injury, quiescent HSCs undergo profound phenotypic changes, including enhanced cell proliferation, loss of lipid droplets, *de novo* expression of α-smooth muscle actin (α-SMA), and excessive production of extracellular matrix, including type I collagen ([@R10]). This process is called *HSC activation*. Freshly-isolated HSCs spontaneously become fully activated in culture ([@R11]), mimicking the process seen *in vivo*. The spontaneous activation of HSCs during cell culture provides a good model for elucidating underlying mechanisms of HSC activation and studying potential therapeutic intervention of the process ([@R10], [@R12]). Few effective medicines are currently available for inhibiting HSC activation and combating hepatic fibrosis, including T2DM- & NASH-associated hepatic fibrosis ([@R13]). It is, therefore, of high priority to identify innocuous anti-fibrotic agents. Curcumin, the yellow pigment in curry from turmeric, has received attention as a promising dietary supplement for the protection against fibrogenic insults ([@R14]). We recently demonstrated that curcumin inhibited HSC activation and protected the liver from CCl~4~-caused injury *in vitro* and *in vivo* ([@R15]--[@R18]).

The liver is not only a site for cleaning AGEs, but also a target organ for AGEs. Elevated levels of serum AGEs were observed in patients with NASH ([@R19]). However, little attention has been paid to effects of AGEs on HSC activation and on T2DM- & NASH-associated hepatic fibrogenesis. AGEs were reported to induce the proliferation of cultured HSCs ([@R20]). The accumulation of AGEs and the reduction of the AGE-R1 abundance may represent important mediators in hyperglycemia-induced HSC activation. However, the underlying mechanism remains largely undefined. The current study was designed to evaluate effects of AGEs on inducing HSC activation, to assess the role of curcumin in inhibiting the effects of AGEs and to explore the underlying mechanisms. Results in this report supported our initial hypothesis that AGEs might stimulate HSC activation, which could be eliminated by curcumin at least partially by inducing AGE-R1 gene expression.

Materials and Methods {#S2}
=====================

AGE preparation and chemicals {#S3}
-----------------------------

AGEs-bovine serum albumin (BSA) were prepared following the protocol described by others ([@R21]). In brief, 50 mg/ml of BSA (USB Corp., Cleveland, OH) and 0.5 M of glucose (Sigma-Aldrich Corp. St. Louis, MO) were dissolved in 0.2 M of sodium phosphate buffer (pH 7.4). A BSA control and a glucose control were respectively prepared by dissolving BSA (50 mg/ml) alone, or glucose (0.5 M) alone, in sodium phosphate buffer (pH 7.4) (0.2 M). After sterilization with sterile Acrodisc® syringe filters, the solutions were incubated in the dark at 37 °C for 60 days. Unbound materials were removed by extensive dialysis against phosphate-buffered saline (PBS).

The concentration of AGEs was determined as described by measuring AGEs-specific fluorescence with excitation at 360 nm and emissions at 440 nm ([@R22], [@R23]). The fluorescence of the BSA control was used as a base line. The fluorescence of qualified AGEs-BSA used in our experiments must be at least 70-fold high than that of the BSA control. The quality and eligibility of AGEs were evaluated and confirmed as suggested ([@R24]). No contamination with insulin-like growth factor-1 and/or endotoxin was detected. Curcumin (purity \>94%) and 15-deoxy-Δ^12,14^-prostaglandin J~2~ (PGJ~2~) were purchased from Sigma (St. Louis, MO). PD68235, a specific PPARγ antagonist, was kindly provided by Pfizer (Ann Arbor, MI) ([@R25]). Rosiglitazone (BRL 49653), purchased from Cayman Chemical (Ann Arbor, MI), was dissolved in dimethyl sulfoxide (100 mM). The ERK inhibitor PD98059 was purchased from CalBiochem (La Jolla, CA, USA). Primary antibodies were purchased from Santa Cruz Biotech. Inc. (Santa Cruz, CA), unless otherwise noted, and were previously described ([@R26]).

Isolation and culture of HSCs {#S4}
-----------------------------

Male Sprague-Dawley rats (200--250g), purchased from the Harlan Laboratories, Inc. (Indianapolis, IN), were housed in a temperature-controlled animal facility (23°C) with a 12:12h light-dark cycle and allowed free access to regular chew and water *ad libitum*. HSCs were isolated by the pronase-collagenase perfusion *in situ* prior to density gradient centrifugation, as we previously described ([@R16]). The animal protocol for use of rats was approved by Institutional Animal Care and Use Committee of Saint Louis University. Freshly-isolated HSCs were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% of fetal bovine serum (FBS) for 48 hr. Cells were passaged in DMEM with 10% of FBS. Semi-confluent HSCs with 4--9 passages were used in experiments. In some of experiments, cells were cultured in serum-depleted DMEM for 24 hr before treatment, which rendered HSCs more sensitive to exogenous stimuli ([@R26]). Cells were subsequently treated and cultured in serum-depleted media, which excluded the interference from other factors in FBS.

Determination of cell proliferation in vitro {#S5}
--------------------------------------------

Cell growth was colorimetrically determined by using the non-radioactive cell proliferation assay kit (*i.e.* MTS assays) (Promega, Madison, WI), following the protocol provided by the manufacturer ([@R16]).

Western blotting analyses {#S6}
-------------------------

Preparation of whole cell extracts, SDS-PAGE, transblotting and subsequent immuno-reactions were conducted as we previously described ([@R16]). β-actin, or β-tubulin, was used as an invariant control for equal loading. Densities of bands in Western blotting analyses were normalized with the internal invariable control. Levels of target protein bands were densitometrically determined by using Quantity One^®^ 4.4.1 (Bio-Rad, Hercules, CA). Variations in the density were expressed as fold changes compared to the control in the blot.

RNA extraction and real-time polymerase chain reaction (PCR) {#S7}
------------------------------------------------------------

Total RNA was treated with DNase I prior to the synthesis of the first strand of cDNA. Real-time PCR were performed as we previously described using SYBR Green Supermix ([@R16]). mRNA levels were expressed as fold changes after normalization with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as described by Schmittgen et al ([@R27]). The following primers were used for determining the level of rat AGE-R1 mRNA by real-time PCR: (F) 5′-GCT CTG ATA TCG GTG ACC CT-3′, (R) 5′-TCG TAG TTG TGG TGG TCG AT-3′. Other primers used in this study have been described in our prior reports ([@R26]).

Plasmids and transient transfection assays {#S8}
------------------------------------------

The cDNA expression plasmids pa-ERK and pdn-ERK, respectively containing a full length of cDNA fragment encoding the constitutively active form of ERK (a-ERK), or the dominant-negative form of ERK (dn-ERK), were previously described and used ([@R28]). The PPARγ activity luciferase reporter plasmid pPPRE-TK-Luc was also previously described ([@R16]). The luciferase reporter plasmid pAGE-R1-Luc was generated by subcloning a fragment (−3838/+67 bp) of the murine AGE-R1 gene promoter into HindIII/MluI sites of pGL3-Basic vector. Semi-confluent HSCs in 6-well cell culture plates were transiently transfected with a total of 3 -- 4.5 μg DNA per well, using the LipofectAMINE^®^ reagent (Invitrogen Corp. Carlsbad, CA), as we previously described ([@R16]). Each sample was in triplicate in every experiment. Transfection efficiency was normalized by co-transfection of the β-galactosidase reporter plasmid pSV-β-gal (0.5 μg/well) (Promega, Madison, WI). β-galactosidase activities were measured by using a chemiluminescence assay kit (Tropix, Bedford, MA). Luciferase activities were expressed as relative unit after normalization with β-galactosidase activities per microgram of protein. Results were combined from at least three independent experiments.

Statistical analyses {#S9}
--------------------

Percentages in differences were calculated in the formula: \[(\# in target HSCs − \# in compared HSCs)/\# in compared HSCs\] × 100% (n≥3). Differences between means were evaluated using an unpaired two-sided Student's test (p\<0.05 considered as significant). Where appropriate, comparisons of multiple treatment conditions with control were analyzed by analysis of variance with the Dunnett's test for post hoc analysis.

RESULTS {#S10}
=======

AGEs stimulated HSC proliferation and induced expression of genes closely relevant to HSC activation {#S11}
----------------------------------------------------------------------------------------------------

To determine effects of AGEs on inducing HSC activation, passaged HSCs were cultured in serum-depleted DMEM for 24 hr, which restored some of quiescent phenotypes and made HSCs more sensitive to exogenous stimuli ([@R26]). Serum-starved HSCs were stimulated with AGEs-BSA, or BSA, at 0--200μg/ml in serum-depleted media for 24 hr. Subsequent culture in serum-depleted DMEM eliminated the interference from growth factors in FBS. As shown in [Fig. 1A](#F1){ref-type="fig"} by cell proliferation assays, AGEs-BSA dose-dependently increased the number of viable cells. For instance, compared with the untreated control (the 1^st^ black column), AGEs-BSA at 100μg/ml significantly increased the number of viable HSCs by 95%. However, BSA by itself had no such stimulatory effect on the number of viable HSCs (white columns). These results suggested that AGEs stimulated cell proliferation of HSCs *in vitro*.

Further experiments by real-time PCR ([Fig. 1B](#F1){ref-type="fig"}) and Western blotting analyses ([Fig. 1C](#F1){ref-type="fig"}) indicated that AGEs-BSA stimulated gene expression of αI(I) collagen and α-SMA, two unique markers for activated HSCs. In addition, AGEs-BSA induced expression of genes relevant to cell growth, including pro-mitogenic PDGF-βR, cyclin D1 and anti-apoptotic Bcl-2, while suppressed gene expression of pro-apoptotic Bax. Furthermore, AGEs-BSA induced expression of genes relevant to pro-fibrogenesis, including the type I and II TGF-β receptors (Tβ-RI/II) and connective tissue growth factor (CTGF). In contrast, BSA by itself had no such dose-dependent effects on the regulation of expression of the genes (data not shown). These results collectively suggested that AGEs induced the activation of HSCs *in vitro*. Since AGEs-BSA at 100 μg/ml was enough for inducing HSC activation, this concentration was chosen for the following experiments.

Curcumin eliminated the effects of AGEs on the induction of HSC activation in vitro {#S12}
-----------------------------------------------------------------------------------

Curcumin by itself has shown its effects on the regulation of expression of genes relevant to the activation of HSCs *in vitro* and *in vivo*, including αI(I) collagen ([@R15], [@R16]), α-SMA ([@R15], [@R16]), TGF-βI/II ([@R17]), CTGF ([@R29], [@R30]), Bax and BcL-2 ([@R17]), etc. To assess the role of curcumin in attenuating the stimulatory effects of AGEs on the activation of HSCs, serum-starved HSCs were treated with or without (w/wt) AGEs-BSA (100μg/ml) in the presence of curcumin at indicated concentrations (0--30 μM) in serum-depleted media for 24 hr. As shown in [Fig. 2A](#F2){ref-type="fig"} by cell proliferation assays, AGEs increased, as expected, the number of viable cells by 92% (the 2^nd^ column), compared with the untreated control (the 1^st^ column). Curcumin dose-dependently eliminated the effect of AGEs. For instance, compared with AGEs alone (the 2^nd^ column), curcumin at 20 μM diminished the effect of AGEs and reduced the number of viable cells by 33% (the 4^th^ column).

Further experiments of real-time PCR ([Fig. 2B](#F2){ref-type="fig"}) and Western blotting analyses ([Fig. 2C](#F2){ref-type="fig"}) revealed that curcumin eliminated the effect of AGEs on regulating expression of genes relevant to the activation of HSCs by reducing gene expression of αI(I) collagen, α-SMA, PDGF-βR, cyclin D1, Bcl-2, Tβ-RI/II and CTGF, as well as by inducing gene expression of Bax, at both levels of mRNA and protein. Taken together, these results demonstrated that curcumin eliminated the effects of AGEs on the induction of HSC activation *in vitro*.

Curcumin abrogated the inhibitory effect of AGEs and induced gene expression of AGE-R1 in passaged HSCs {#S13}
-------------------------------------------------------------------------------------------------------

To elucidate the underlying mechanism by which curcumin eliminated the effects of AGEs on the induction of HSC activation, we assumed that one of the mechanisms for AGEs to induce HSC activation was to suppress gene expression of AGE-R1, which could be attenuated by curcumin by inducing gene expression of AGE-R1. To test the assumption, serum-starved HSCs were stimulated with AGEs at indicated doses in serum-depleted media for 24 hr w/wt the presence of curcumin (0--30 μM). As shown in [Fig. 3A & B](#F3){ref-type="fig"} respectively by real-time PCR and Western blotting analyses, AGEs dose-dependently suppressed gene expression of AGE-R1. For instance, compared with the untreated control (the 1^st^ column and lane), AGEs at 100 μg/ml significantly reduced AGE-R1 at both levels of transcript and protein by approximately 70% (the 5^th^ column and lane).

To evaluate the role of curcumin in regulating expression of AGE-R1, passaged HSCs were treated with curcumin at various concentrations in DMEM with 10% FBS for 24 hr. Western blotting analyses indicated that curcumin by itself increased the abundance of AGE-R1 in HSCs in a dose-dependent manner ([Fig. 3C](#F3){ref-type="fig"}). Additional experiments revealed that curcumin dose-dependently attenuated the effect of AGEs by increasing gene expression of AGE-R1 demonstrated by real-time PCR ([Fig. 3D](#F3){ref-type="fig"}) and Western blotting analyses ([Fig. 3E](#F3){ref-type="fig"}). For example, compared with AGEs alone (the 2^nd^ column and lane), curcumin at 20 μM diminished the effect of AGEs and increased the levels of mRNA and protein by more than 150% (the 4^th^ column and lane). Prior studies have shown that serum-starvation partially restored phenotypic features of quiescent HSCs, including reduced levels of αI(I) collagen and α-SMA ([@R26]). However, HSCs in [Fig. 3C](#F3){ref-type="fig"} were cultured in regular DMEM with 10% of FBS, which inhibited gene expression of AGE-R1 in HSCs. The difference in media conditions prior to the treatment could cause a difference in the basal levels of AGE-R1 in the un-treated controls in [Fig. 3C verse B and E](#F3){ref-type="fig"}. Take together, our results demonstrated that curcumin eliminated the inhibitory effect of AGEs and induced gene expression of AGE-R1 in passaged HSCs.

The inhibition of ERK activity diminished the effect of AGEs and induced gene expression of AGE-R1 in cultured HSCs {#S14}
-------------------------------------------------------------------------------------------------------------------

To start to elucidate the mechanisms by which curcumin eliminated the effect of AGEs on inhibiting gene expression of AGE-R1 in HSCs, we presumed that AGEs stimulated the activity of ERK in HSCs, leading to the suppression of gene expression of AGE-R1, and that curcumin induced gene expression of AGE-R1 by inhibiting the activity of ERK in HSCs. We have shown that curcumin by itself dose-dependently reduces the level of phosphorylated ERK in cultured HSCs ([@R31]). Our prior experiments showed that the acute activation of ERK could reach its peak within 20--30 minutes in passaged HSCs after the exposure to stimuli, which was attenuated and inhibited by curcumin ([@R26], [@R32]). To test our presumption, serum-starved HSCs were treated with AGEs at indicated doses in serum-depleted media for 30 minutes w/wt the pretreatment with curcumin (0--30 μM) for 1 hr. Whole cell extracts were prepared for analyzing levels of phosphorylated ERK. As shown in [Fig. 4A](#F4){ref-type="fig"} by Western blotting analyses, AGEs caused a dose-dependent increase in the level of phosphorylated ERK, indicating that AGEs indeed induced the activation of ERK in HSCs *in vitro*. The inductive effect of AGEs on the level of phosphorylated ERK was diminished by curcumin in a dose-dependent manner ([Fig. 4B](#F4){ref-type="fig"}).

To evaluate the role of the activation of ERK in regulating gene expression of AGE-R1, serum-starved HSCs were pretreated w/wt the selective ERK inhibitor PD98059 (0--20 μM) or curcumin (20 μM) for 1 hr prior to the exposure to AGEs (100 μg/ml) for additional 24 hr. Total RNA and whole cell extracts were prepared from the cells. As shown by real-time PCR ([Fig. 4C](#F4){ref-type="fig"}) and Western blotting analyses ([Fig. 4D](#F4){ref-type="fig"}), compared with the untreated control (the 1^st^ column and lane), AGEs reduced, as expected, the levels of mRNA and protein of AGE-R1 (the 2^nd^ column and lane). The inhibition of ERK activity by PD98059, mimicking the role of curcumin (the last column and lane), dose-dependently eliminated the inhibitory effect of AGEs and elevated the contents of AGE-R1 mRNA and protein in the cells (the 3^rd^ -- 5^th^ columns and lanes). These results collectively supported our presumption and suggested that the stimulation of ERK activity by AGEs might lead to the suppression of gene expression of AGE-R1, which could be abrogated by curcumin by inhibiting the activity of ERK in HSCs.

The alterations in the activity of ERK resulted in the changes in the gene promoter activity and the abundance of AGE-R1 in cultured HSCs {#S15}
-----------------------------------------------------------------------------------------------------------------------------------------

To verify the role of the ERK activity in mediating the effect of AGEs on regulating gene expression of AGE-R1, HSCs in six-well culture plates were co-transfected with a DNA mixture, including 2 μg of the AGE-R1 gene promoter luciferase reporter plasmid pAGE-R1-Luc, 0.5 μg of pSV-β-gal and 0.7 μg of the cDNA expression plasmid pa-ERK encoding the constitutively active form of ERK at various doses plus the empty vector pcDNA, or 1.5 μg of the cDNA expression plasmid pdn-ERK encoding the dominant negative form of ERK (dn-ERK) at various doses plus the empty vector pcDNA. The latter was used to ensure equal amount of total DNA in transfection assays. After recovery, cells were serum-starved for 4 hr prior to the treatment w/wt AGEs (100 μg/ml) in the presence or absence of curcumin (20 μM) in serum-depleted media for additional 24 hr. Results from luciferase activity assays in [Fig. 5A & B](#F5){ref-type="fig"} demonstrated that compared with the untreated control (the corresponding 1^st^ column), AGEs significantly reduced, as expected, the luciferase activity in the cells, indicating a reduction in the promoter activity of AGE-R1 gene (the corresponding 2^nd^ column). Curcumin apparently eliminated the inhibitory effect of AGEs on the gene promoter activity AGE-R1 (the corresponding 3^rd^ column). It was further observed that forced expression of exogenous active ERK cDNA dose-dependently diminished the role of curcumin and reduced luciferase activities in the cells (the 4^th^--6^th^ columns in [Fig. 5A](#F5){ref-type="fig"}). Compared with the control (the 1^st^ column), the co-transfection of pa-ERK alone, as a control, significantly reduced the luciferase activity in the cells (the last column in [Fig. 5A](#F5){ref-type="fig"}). These results confirmed that the increase in ERK activity could reduce the gene promoter activity of AGE-R1 in HSCs. In contrast, forced expression of exogenous dn-ERK cDNA diminished the effect of AGEs and increased, like curcumin (the 3^rd^ column in [Fig. 5B](#F5){ref-type="fig"}), luciferase activities in a dose-dependent manner (the 4^th^ -- 6^th^ columns in [Fig. 5B](#F5){ref-type="fig"}), indicating that the blockade of the ERK signaling pathway by dn-ERK abrogated the effect of AGEs on the inhibition of the promoter activity of AGE-R1 gene.

To further confirm the role of the curcumin-caused inhibition of ERK in the up-regulation of expression of AGE-R1, serum-starved HSCs were treated with AGEs (100 μg/ml) in the presence of curcumin (20 μM), or the ERK selective inhibitor PD98059 (10 μM) in serum-depleted media for 24 hr. Western blotting analyses indicated that compared with the untreated control (the 1^st^ lane), AGEs reduced, as expected, the abundance of AGE-R1 in HSCs (the 2^nd^ lane). It is of interest to observe that the ERK inhibitor PD98059 (the 5^th^ lane) mimicked the role of curcumin (the 5^th^ lane) in the attenuation of the inhibitory effect of AGEs and in the elevation of the level of AGE-R1 in HSCs. PD98059 (the ^3rd^ lane) or curcumin (the 4^th^ lane) alone showed a slight effect on the elevation of the level of AGE-R1 in serum-starved HSCs, likely because of no enough stimuli in serum-depleted media. Taken together, our results indicated that the alterations in the activity of ERK resulted in the changes in the gene promoter activity of AGE-R1 and in the abundance of AGE-R1 in cultured HSCs. Our results also revealed a critical role of the curcumin-caused inhibition of ERK in the up-regulation of expression of AGE-R1.

AGEs suppressed gene expression of PPARγ and reduced its trans-activity in HSCs, which were diminished by curcumin {#S16}
------------------------------------------------------------------------------------------------------------------

PPARγ is highly expressed in quiescent HSCs in the normal liver ([@R33]). However, the level of PPARγ and its activity are dramatically reduced during the process of HSC activation *in vitro* and *in vivo* ([@R33]). We previously reported that curcumin induced gene expression of PPARγ *in vitro* and *in vivo* ([@R15]--[@R17]), which was required for curcumin to inhibit HSC activation *in vitro* ([@R16], [@R17]). To further elucidate the underlying mechanisms by which curcumin eliminated the effect of AGEs and induced gene expression of AGE-R1 in HSCs, we assumed that AGEs suppressed gene expression of PPARγ in HSCs, which was abolished by curcumin. To test the assumption, serum-starved HSCs were stimulated w/wt AGEs (100 μg/ml) in the presence of curcumin (0--30 μM) in serum-depleted media for 24 hr. Total RNA and whole cell extracts were prepared from the cells. As shown by real-time PCR ([Fig. 6A](#F6){ref-type="fig"}) and Western blotting analyses ([Fig. 6B](#F6){ref-type="fig"}), compared with the untreated control (the 1^st^ column and lane), AGEs significantly reduced gene expression of PPARγ (the 2^nd^ column and lane). The inhibitory effect of AGEs was dose-dependently diminished by curcumin (the 3^rd^ -- 5^th^ columns and lanes).

To evaluate the effect of AGEs on the *trans*-activity of PPARγ, HSCs were transfected with the PPARγ activity luciferase reporter plasmid pPPRE-Luc. After recovery, cells were serum-starved for 4 hr prior to the treatment w/wt AGEs (100 μg/ml) in the presence of curcumin (0--30 μM) in serum-depleted media with PGJ~2~ (5 μM) for additional 24 hr. The exogenous PPARγ agonist PGJ~2~ was added because there was no PPARγ agonist in serum-depleted media. Results from luciferase activity assays indicated that compared with the untreated control (the 1^st^ column), AGEs reduced luciferase activity by 59% (the 2^nd^ column), suggesting a significant reduction in the *trans*-activity of PPARγ in the cells. The inhibitory effect of AGEs was dose-dependently eliminated by curcumin (the 3^rd^ --5^th^ columns). These results collectively demonstrated that AGEs suppressed gene expression of PPARγ and reduced its *trans*-activity in HSCs, which were diminished by curcumin by inducing gene expression of PPARγ.

The activation of PPARγ eliminated the inhibitory effect of AGEs and stimulated gene expression of AGE-R1 in HSCs in vitro {#S17}
--------------------------------------------------------------------------------------------------------------------------

To evaluate the role of the activation of PPARγ in regulating the gene promoter activity of AGE-R1, HSCs were transfected with the AGE-R1 gene promoter luciferase reporter plasmid pAGE-R1-Luc. After recovery, cells were serum-starved for 4 hr prior to the treatment w/wt AGEs (100 μg/ml) in the presence or absence of the natural PPARγ agonist PGJ~2~, or the synthesized PPARγ agonist rosiglitazone (Rosi), at 0--10 μM in serum-depleted media for additional 24 hr. Results from luciferase activity assays in [Fig. 7A](#F7){ref-type="fig"} demonstrated that compared with the untreated control (the corresponding 1^st^ column), AGEs significantly reduced, as expected, luciferase activity in the cells (the corresponding 2^nd^ column). The inhibitory effect of AGEs was dose-dependently abrogated by either PGJ~2~ or rosiglitazone (the corresponding 3^rd^ -- 5^th^ columns), suggesting that the activation of PPARγ eliminated the inhibitory effect of AGEs on the gene promoter activity of AGE-R1 in passaged HSCs.

To verify the role of the activation of PPARγ in inducing gene expression of AGE-R1, serum-starved HSCs were stimulated w/wt AGEs (100 μg/ml) in the presence of the PPARγ agonist PGJ~2~, or rosiglitazone (Rosi) at 0--10 μM in serum- depleted media for 24 hr. Results from real-time PCR ([Fig. 7B](#F7){ref-type="fig"}) and Western blotting analyses ([Fig. 7C](#F7){ref-type="fig"}) demonstrated that the activation of PPARγ by PGJ~2~ or rosiglitazone eliminated the inhibitory effect of AGEs and dose-dependently induced gene expression of AGE-R1 at the levels of transcript and protein in the cells (the corresponding 3^rd^ -- 5^th^ columns and lanes).

Additional experiments were conducted to address the question whether the stimulation of the AGE-R1 gene expression in HSCs by PGJ~2~ or rosiglitazone corresponded to an increase in PPARγ. HSCs were treated w/wt AGEs (100 μg/ml) in the presence of PGJ~2~, or rosiglitazone at 0--10 μM in serum-depleted media for 24 hr. Western blotting analyses in [Fig. 7D](#F7){ref-type="fig"} demonstrated that PGJ~2~ or rosiglitazone, mimicking the role of curcumin ([Fig. 6B](#F6){ref-type="fig"}), dose-dependently eliminated the effect of AGEs on the level of PPARγ in HSCs *in vitro*. To our knowledge, the role of the PPARγ agonist PGJ~2~, or rosiglitazone, in inducing gene expression of PPARγ in HSCs has never been reported. Taken together, our results demonstrated that the activation of PPARγ eliminated the inhibitory effect of AGEs and stimulated gene expression of AGE-R1 in HSCs *in vitro*.

The stimulation of the *trans*-activity of PPARγ played a critical role in the curcumin-caused elimination of the effect of AGEs on the inhibition of gene expression of AGE-R1 in HSCs *in vitro* {#S18}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To further evaluate the role of the activation of PPARγ in the curcumin-caused elimination of the inhibitory effect of AGEs on gene expression of AGE-R1, serum-starved HSCs were pretreated w/wt the PPARγ antagonist PD68235 (20 μM) for 30 min prior to the exposure to AGEs (100 μg/ml), or curcumin (20 μM), or both, in serum-depleted media with PGJ~2~ (5 μM) for additional 24 hr. Total RNA and whole cell extracts were prepared for real-time PCR ([Fig. 8A](#F8){ref-type="fig"}) and Western blotting analyses ([Fig. 8B](#F8){ref-type="fig"}). Compared with the untreated control (the 1^st^ column and lane), AGEs significantly reduced the levels of mRNA and protein of AGE-R1 in the cells (the 2^nd^ column and lane). Curcumin, as expected, dramatically eliminated the effect of AGEs and increased the contents of mRNA and protein of AGE-R1 (the 3^rd^ column and lane). It was of interest to observe that the blockade of PPARγ activation by the pretreatment with the PPARγ antagonist PD68235 (PD) apparently attenuated the role of curcumin in eliminating the inhibitory effect of AGEs (the last column and lane), suggesting a critical role of the activity of PPARγ in the process. PD68235 alone had no apparent effect (the 4^th^ column and lane). These results collectively indicated that the stimulation of the *trans*-activity of PPARγ played a critical role in the curcumin-caused elimination of the effect of AGEs on the inhibition of gene expression of AGE-R1 in HSCs *in vitro*.

ERK and PPARγ acted sequentially in the attenuation of the effect of AGEs on the regulation of the expression of AGE-R1 in HSCs {#S19}
-------------------------------------------------------------------------------------------------------------------------------

To elucidate the relationship between the ERK signaling pathway and the activation of PPARγ in regulating gene expression of AGE-R1, passaged HSCs in six-well plates were co-transfected with a total of 4.5 μg of a DNA mixture per well, including 2 μg of the promoter activity luciferase reporter plasmid pAGE-R1-Luc, 0.5μg of pSV-β-gal and 2 μg of the cDNA expression plasmid pa-ERK, encoding constitutively active ERK, at indicated doses plus the empty vector pcDNA. The latter was used to ensure an equal amount of total DNA in transfection assays. After overnight recovery from transfection, cells were serum-starved for 4 hr prior to the treatment w/wt AGEs (100 μg/ml) in the presence or absence of PGJ~2~ (5 μM) in serum-depleted media for additional 24 hr. As shown in [Fig. 9](#F9){ref-type="fig"}, compared to the untreated control (the 1^st^ column), AGEs significantly reduced, as expected, luciferase activity in cells transfected with pAGE-R1-Luc (the 2^nd^ column). Forced expression of constitutively active ERK potentiated the inhibitory effect of AGEs (the 3^rd^ column). On the other hand, the activation of PPARγ with PGJ~2~ dramatically diminished the inhibitory effect of AGEs (the 4^th^ column). It was of interest to observe that forced expression of constitutively active ERK eliminated the role of PGJ~2~ and reduced luciferase activities in a dose-dependent manner (the 4^th^ -- 7^th^ columns), indicating that the activation of the ERK signaling pathway counteracted the role of PPARγ activation in stimulating the promoter activity of AGE-R1. This result suggested a sequential relationship between ERK and PPARγ in regulating the promoter activity of AGE-R1 in HSCs.

To further elucidate the relationship between ERK and PPARγ in the attenuation of the inhibitory effect of AGEs on the regulation of gene expression of AGE-R1, serum-starved HSCs were treated with AGEs (100 μg/ml) and the PPARγ agonist PGJ~2~ (5 μM) plus or minus the ERK selective inhibitor PD98059 (10 μM) in serum-depleted media for 24 hr. Western blotting analyses in [Fig. 9B](#F9){ref-type="fig"} revealed that compared with the untreated cells (the 1^st^ lane), PGJ~2~ by itself increased the level of AGE-R1 (the 5^th^ lane). AGEs significantly reduced the level of AGE-R1 in HSCs (the 2^nd^ lane), which was dramatically attenuated, as expected, by the activation of PPARγ by PGJ~2~ (the 3^rd^ lane). It was further shown that the presence of PD98059 strengthened the role of PGJ~2~ in the attenuation of the inhibitory effect of AGEs on the expression of AGE-R1 in HSCs (the 4^th^ lane). Taken together, our results suggested a sequential relationship between upstream ERK and downstream PPARγ in the attenuation of the effect of AGEs on the regulation of the expression of AGE-R1 in HSCs.

DISCUSSION {#S20}
==========

The development of T2DM is coupled with the increase in the levels of many detrimental factors, some of which stimulate the activation of HSCs, including hyperinsulinemia ([@R26]), hyperleptinemia ([@R34]), dyslipidemia ([@R35], [@R36]) and hyperglycemia ([@R37]). Our present study provided the evidence that AGEs, whose formation is facilitated and stimulated by hyperglycemia, were an additional stimulus for inducing HSC activation. AGE-R1 has been reported to have functions in detoxification and clearance of AGEs ([@R7]). The current study was designed to evaluate effects of AGEs on inducing HSC activation, to assess the role of curcumin in diminishing the AGE effects and to explore the underlying mechanisms. We observed that AGEs induced the activation of HSCs and suppressed gene expression of AGE-R1 in activated HSCs. The phytochemical curcumin eliminated the effects of AGEs and induced gene expression of AGE-R1 likely by inhibiting ERK activity and stimulating the *trans*-activity of PPARγ.

AGEs elicit their effects via receptors. While AGE-R1 and other receptors, including CD36 and Scr-II, assist AGE clearance, RAGE facilitates pro-inflammation ([@R7], [@R38]). The AGEs-RAGE-OS axis is involved in diabetic complications ([@R3]). A dramatic increase in RAGE expression is found in diabetic patients with high levels of plasma AGEs ([@R8], [@R39]). On the other hand, the AGE-R1 abundance is significantly reduced in diabetic kidney ([@R9]), suggesting a possible inverse relationship between AGEs-mediated cell injury and low expression of AGE-R1. Over-expression of AGE-R1 reduces basal levels of AGEs and OS, enhances resistance to hyperglycemia and protects against inflammation *in vivo* ([@R40]). Inhibition of AGE formation, blockade of AGEs-RAGE interaction, suppression of RAGE expression, interruption of its signaling and induction of AGE-R1 expression are, thus, novel therapeutic strategies for treatment of diabetic complications ([@R41]). To our knowledge, this study is the first report to observe that AGEs suppressed gene expression of AGE-R1 in passaged HSCs, which could be eliminated by curcumin. Prior studies suggested that AGE-R1 might be a negative regulator in the inflammatory response to AGEs in mesangial cells ([@R7]). It was also reported that an increase in the dietary AGE contents reduced the ratio of AGE-R1 to RAGE in cells, leading to an increase in oxidative stress and organ damage, and a reduction in life span ([@R42]). In addition to the induction of gene expression of AGE-R1 in HSCs, our preliminary results also suggested that curcumin inhibited gene expression of RAGE in HSCS *in vitro* (data not shown). Additional experiments are ongoing in our lab to elucidate molecular mechanisms by which curcumin divergently regulated gene expression of RAGE and AGE-R1 in HSCs.

Oxidative stress induces HSC activation and hepatic fibrogenesis ([@R10]). Studies have suggested that AGE-R1 is not only a scavenger receptor which facilitates uptake and degradation of AGEs, but also a receptor mediating the attenuation of oxidative stress ([@R43]). Therefore, the curcumin-caused induction of gene expression of AGE-R1 could attenuate oxidative stress in passaged HSCs, leading to the inhibition of the AGEs-induced activation of HSCs. On the other hand, curcumin itself is a potent antioxidant, whose antioxidant capacity is 100-fold stronger than that of vitamin E/C ([@R44]), likely by inducing gene expression of glutamate-cysteine ligase, a key rate-limiting enzyme in *de novo* synthesis of glutathione ([@R18]). It is plausible to assume that in addition to the induction of AGE-R1 gene expression, curcumin itself could attenuate oxidative stress, which also facilitates the inhibition of the AGEs-induced activation of HSCs.

As demonstrated in the report, AGEs inhibited gene expression of AGE-R1, which could be diminished by the activation of PPARγ by PGJ~2~ or rosiglitazone ([Fig. 7C](#F7){ref-type="fig"}). It was explained that a portion of the stimulatory role of PGJ~2~ might be used to counteract the inhibitory effect of AGEs. Therefore, the effect of PGJ~2~ alone on elevating the level of AGE-R1 was more prominent than that of the treatment with both PGJ~2~ and AGEs ([Fig. 9B](#F9){ref-type="fig"}). On the other hand, our results could not exclude other possible mechanisms by which the activation of PPARγ by PGJ~2~ elevated the abundance of AGE-R1, including increasing the protein stability and/or mRNA half-life of AGE-R1 in HSCs *in vitro*.

Our results in this report indicated that AGEs stimulated the activation of ERK, suppressed gene expression of PPARγ and reduced its *trans*-activation activity in activated HSCs *in vitro*. Our results also suggested a sequential relationship between upstream ERK and downstream PPARγ in the attenuation of the effect of AGEs on the regulation of the expression of AGE-R1 in HSCs. Our observations were in agreement with prior other reports ([@R45], [@R46]). The activation of mitogen-activated protein kinase (MAPK) signaling pathways stimulates the phosphorylation of PPARγ, resulting in a reduction in the *trans*-activation activity of the nuclear transcription factor ([@R45], [@R46]). We demonstrated that curcumin inhibited the activity of ERK and induced gene expression of PPARγ in passaged HSCs ([@R16], [@R17]), both of which attenuated the inhibitory effects on the promoter activity of AGE-R1 in HSCs. It is, therefore, understandable that curcumin could eliminate the effect of AGEs and induce gene expression of AGE-R1 in HSCs. It is worth mentioning that the pharmacological approach, *i.e.* using the selective ERK inhibitor, might not be the best, but a proper one, to address the questions studied in this report. Additional experiments are necessary to elucidate the underlying molecular mechanisms of the PPARγ-dependent ERK signaling pathway in regulating the promoter activity of AGE-R1 in HSCs. However, it is noteworthy that our results did not exclude possible PPARγ-independent effects of the ERK pathway on inhibiting the promoter activity of AGE-R1 in HSCs.

The toxicity of curcumin to cultured HSCs was previously evaluated ([@R16]). Based on results from lactate dehydrogenase release assays, trypan blue exclusion assays and a rapid recovery of cell proliferation after withdrawal of curcumin, it was concluded that curcumin up to 100 μM was not toxic to cultured HSCs. Curcumin at 20 μM was used in most of our *in vitro* experiments. The systemic bioavailability of curcumin is relatively low ([@R47]). Curcumin concentrations in human plasma can reach up to 2 μM following oral intake of very high amounts of curcumin ([@R48]). Few reports could be found regarding serum levels of the AGE-proteins in human populations with or without diabetes. Among these limited studies, the levels of serum AGEs in human were not consistent ([@R49]--[@R53]). AGEs at 100 μg/ml was used in most of experiments in this project. The same dose of human glycated albumin was also used to examine its effects on insulin signaling in L6 skeletal muscle cells ([@R24]). The concentration of AGEs used in our experiments was determined by measuring AGEs-specific fluorescence with excitation at 360 nm and emissions at 440 nm ([@R22], [@R23]). N-carboxymethyl-lysine (CML) was a major AGE among them ([@R22], [@R23]). The level of CML was previously observed to be higher in diabetic patients than non-diabetic controls ([@R51]). It is noteworthy that because the *in vivo* system is multi-factorial, directly extrapolating *in vitro* conditions and results, *e. g.* effective concentrations, to the *in vivo* system, or vice versa, might be misleading.

Prior studies showed the role of curcumin in inhibiting the AGEs-induced increase in NF-kB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular endothelial cells ([@R54]). The influence of curcumin on the level of AGEs and the cross-linking of collagen in diabetic rats were studied ([@R55]). A correlation between the level of AGEs and collagen cross-linking was noted. It was further found that accelerated accumulation of AGE-collagen in diabetic animals was prevented by curcumin. The preventive effect of curcumin on the advanced glycation and cross-linking of collagen was pronounced. Results from this report demonstrated the role of curcumin administration in the prevention of AGE-induced complications of diabetes mellitus ([@R55]). Additional *in vivo* experiments are necessary to verify the *in vitro* observed protective role of curcumin in attenuating the AGE effects on the activation of HSCs.

In conclusion, results in this report supported our initial hypothesis and demonstrated that AGEs stimulated HSC activation, which was eliminated by curcumin at least partially by inducing AGE-R1 gene expression. This process was likely mediated by inhibiting ERK activity, inducing gene expression of PPARγ and sequentially stimulating its *trans*-activity. These results were summarized in [Fig. 10](#F10){ref-type="fig"}. The authors admit that the evidence presented in this report is somewhat indirect. Experiments with high expression of AGE-R1 in HSCs by stable transfection with exogenous AGE-R1 cDNA, and knockdown expression of AGE-R1 by RNA interference technology, including small interfering RNA, would provide more direct evidence to the involvement and role of AGE-R1 in mediating the curcumin inhibition of AGE-induced HSC activation. These experiments are ongoing in our laboratory. It bears emphasis that our results do not exclude any other mechanisms by which curcumin eliminates the stimulatory effects of AGEs on the activation of HSCs and induces gene expression of AGE-R1 in HSCs. It remains unknown how the curcumin-caused inhibition of ERK and stimulation of PPARγ activity could result in the induction of gene expression of AGE-R1 in HSCs. Additional experiments are necessary to explore the underlying molecular mechanisms. The results from this study provide novel insight into effects of diabetes-associated AGEs on inducing HSC activation and hepatic fibrogenesis, the roles and underlying mechanisms of curcumin in abrogating the stimulatory effects of AGEs.

The work was supported by the grant DK 47995 from NIH/NIDDK to A. Chen.

AGEs

:   advanced glycation end-products

AGE-R1

:   AGE receptor-1

α-SMA

:   alpha-smooth muscle actin

BSA

:   bovine serum albumin

CTGF

:   connective tissue growth factor

DMEM

:   Dulbecco's modified Eagle's medium

FBS

:   fetal bovine serum

GAPDH

:   glyceraldehyde-3-phosphate dehydrogenase

HSCs

:   hepatic stellate cells

NASH

:   non-alcoholic steatohepatitis

PDGF-βR

:   platelet-derived growth factor-beta receptor

PPARγ

:   peroxisome proliferator-activated receptor-gamma

RAGE

:   the receptor for AGEs

TGF-βR

:   transforming growth factor-beta receptor

![AGEs dose-dependently stimulated HSC activation in vitro\
HSCs were serum-starved in DMEM for 24 hr prior to the stimulation with AGEs-BSA, or BSA, at indicated doses in serum-depleted media for additional 24 hr. (**A**) Cell proliferation was determined by colorimetric MTS assays. Results were expressed as fold changes in the number of viable cells, compared with the untreated control (mean± s. d., n=3) (the corresponding 1^st^ column). The percentage in difference was calculated in the formula: \[(\# in target HSCs − \# in compared HSCs)/\# in compared HSCs\] x 100%. \*p\<0.05 vs. the untreated control (the 1^st^ column). (**B**) real-time PCR analyses. Values were presented as mRNA fold changes (mean ± s. d., n=3). \*p\<0.05 vs. the untreated control (the corresponding 1^st^ column). (**C**) Western blotting analyses. Representatives were from three independent experiments. β-actin was used as an internal control for equal loading. *Italic* numbers beneath blots were fold changes (means ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.](nihms352078f1){#F1}

![Curcumin eliminated the effects of AGEs on the induction of HSC activation\
Serum-starved HSCs were treated with or without AGEs-BSA at 100 μg/ml plus or minus curcumin at indicated concentrations in serum-depleted media for 24 hr. (**A**) Cell proliferation was determined by MTS assays. Results were expressed as fold changes in the number of viable cells, compared with the untreated control (mean± s. d., n=3). \*p\<0.05 vs. the untreated control (the 1^st^ column); ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the 2^nd^ column). The percentage in difference was calculated in the formula: \[(\# in target HSCs − \# in compared HSCs)/\# in compared HSCs\] x 100%. (**B**) real-time PCR analyses. Values were presented as mRNA fold changes (mean ± s. d., n=3). \*p\<0.05 vs. the untreated control; ^‡^*p*\<0.05 vs. cells treated with AGEs alone. (**C**) Western blotting analyses. Representatives were from three independent experiments. β-actin was used as an internal control for equal loading. *Italic* numbers beneath blots were fold changes (means ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.](nihms352078f2){#F2}

![Curcumin abrogated the effect of AGEs and induced gene expression of AGE-R1 in cultured HSCs\
Serum-starved HSCs were treated with AGEs at 0--200 μg/ml (A & B), or with AGEs at 100 μg/ml plus curcumin at indicated concentrations (D & E), in serum-depleted media for 24 hr. On the other hand, passaged HSCs were treated with curcumin at indicated concentrations in DMEM with 10% FBS for 24 hr (C).\
**A** & **D**: Real-time PCR analyses. Values were presented as mRNA fold changes (mean ± s. d., n=3). \**p*\<0.05 vs. the untreated control (the 1^st^ column), ^‡^*p*\<0.05 vs. the cells treated with AGEs alone (the 2^nd^ column).\
**B, C,** & **E**: Western blotting analyses. Representatives were from three independent experiments. β-tubulin was used as an internal control for equal loading. *Italic* numbers beneath blots were fold changes (means ± s. d.) in the densities of the bands compared with the control without treatment in the blot (n=3), after normalization with the internal invariable control.](nihms352078f3){#F3}

![The inhibition of ERK activity diminished the effect of AGEs and induced gene expression of AGE-R1 in cultured HSCs\
(**A** & **B**) Serum-starved HSCs were treated with AGEs at indicated doses in serum-depleted media for 30 minutes with or without the pretreatment with curcumin (0--30 μM) for 1 hr. Whole cell extracts were prepared for analyzing levels of phosphorylated ERK by Western blotting analyses. Total ERK was used as an internal control for equal loading. *Italic* numbers beneath blots were fold changes (mean ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control. Representatives were from three independent experiments.\
(**C** & **D**) Serum-starved HSCs were pretreated with or without the selective ERK inhibitor PD98059 (0--20 μM) or curcumin (20 μM) for 1 hr prior to the exposure to AGEs (100 μg/ml) for additional 24 hr. Total RNA and whole cell extracts were prepared from the cells. (**C**) real-time PCR assays. Values were presented as mRNA fold changes (mean ± s. d., n=3). \**p*\<0.05 vs. cells with no treatment (the 1^st^ column). ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the 2^nd^ column). (**D**) Western blotting analyses. β-tubulin was used as an internal control for equal loading. Representatives were from three independent experiments. *Italic* numbers beneath blots were fold changes (mean ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.](nihms352078f4){#F4}

![The alterations in the activity of ERK resulted in the changes in the gene promoter activity and the abundance of AGE-R1 in cultured HSCs\
(**A** & **B**) HSCs were co-transfected with the AGE-R1 promoter luciferase reporter plasmid pAGE-R1-Luc and the cDNA expression plasmid pa-ERK encoding constitutively active ERK (**A**), or pdn-ERK encoding dominant negative ERK (**B**), at indicated doses. After recovery, cells were serum-starved for 4 hr prior to the treatment with or without AGEs (100 μg/ml) in the presence or absence of curcumin (20 μM) in serum-depleted media for additional 24 hr. Luciferase activity assays were conducted (n=6). \**p*\<0.05 vs. cells with no treatment (the 1^st^ column). ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the 2^nd^ column). ^§^*p*\<0.05 vs. cells treated with AGEs plus curcumin (the 3^rd^ column). The floating schema denoted the plasmids pAGE-R1-Luc and pa-ERK, or pdn-ERK in use for co-transfection.\
**(C)** Serum-starved HSCs were treated with AGEs (100 μg/ml) in the presence of curcumin (20 μM), or the ERK selective inhibitor PD98059 (10 μM), in serum-depleted media for 24 hr. Western blotting analyses were conducted. β-tubulin was used as an internal control for equal loading. Representatives were from three independent experiments. *Italic* numbers beneath blots were fold changes (mean ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.](nihms352078f5){#F5}

![AGEs suppressed gene expression of PPARγ and reduced its trans-activity in HSCs, which were diminished by curcumin\
(**A** & **B**) Serum-starved HSCs were stimulated with or without AGEs (100 μg/ml) in the presence of curcumin (0--30 μM) in serum-depleted media for 24 hr. Total RNA and whole cell extracts were prepared. (**A**). real-time PCR assays. Values were presented as mRNA fold changes (mean ± s. d., n=3). \**p*\<0.05 vs. cells with no treatment (the 1^st^ column). ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the 2^nd^ column). (**B**) Western blotting analyses. β-actin was used as an internal control for equal loading. Representatives were from three independent experiments. *Italic* numbers beneath blots were fold changes (mean ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.\
(**C**) HSCs were transfected with the PPARγ activity luciferase reporter plasmid pPPRE-Luc. After recovery, cells were serum-starved for 4 hr prior to the treatment with or without AGEs (100 μg/ml) in the presence of curcumin (0--30 μM) in serum-depleted media with PGJ~2~ (5 μM) for 24 hr. Luciferase activity assays were conducted (n=6). \**p*\<0.05 vs. cells with no treatment (the 1^st^ column), ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the 2^nd^ column). The floating schema denoted the plasmid pPPRE-Luc in use for transfection and the application of AGEs w/wt curcumin to the system.](nihms352078f6){#F6}

![The activation of PPARγ eliminated the inhibitory effect of AGEs and stimulated gene expression of AGE-R1 in HSCs in vitro\
(**A**) HSCs were transfected with the AGE-R1 promoter luciferase reporter plasmid pAGE-R1-Luc. After recovery, cells were serum-starved for 4 hr prior to the treatment with or without AGEs (100 μg/ml) in the presence of PGJ~2~, or rosiglitazone (Rosi), at 0--10 μM in serum-depleted media for 24 hr. Luciferase activity assays were conducted (n=6). \**p*\<0.05 vs. cells with no treatment (the corresponding 1^st^ column). ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the corresponding 2^nd^ column). The floating schema denoted pAGE-R1-Luc in use for transfection and the application of PGJ~2~, or Rosi, to the system.\
(**B**, **C** & **D**) Serum-starved HSCs were stimulated with or without AGEs (100 μg/ml) in the presence of PGJ~2~, or Rosi, at 0--10 μM in serum-depleted media for 24 hr. Total RNA and whole cell extracts were prepared. (**B**). real-time PCR assays. Values were presented as mRNA fold changes (mean ± s. d., n=3). \**p*\<0.05 vs. cells with no treatment (the corresponding 1^st^ column). ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the corresponding 2^nd^ column). (**C** & **D**) Western blotting analyses. β-tubulin, or β-actin, was used as an internal control for equal loading. Representatives were from three independent experiments. *Italic* numbers beneath blots were fold changes (mean ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.](nihms352078f7){#F7}

![The stimulation of the trans-activity of PPARγ played a critical role in the curcumin-caused elimination of the effect of AGEs on inhibiting gene expression of AGE-R1 in HSCs in vitro\
Serum-starved HSCs were pretreated w/wt the PPARγ antagonist PD68235 (PD) (20 μM) for 30 min prior to the exposure to AGEs (100 μg/ml), or curcumin (20 μM), or both, in serum-depleted media with PGJ~2~ (5 μM) for additional 24 hr. Total RNA and whole cell extracts were prepared. (**A**). real-time PCR assays. Values were presented as mRNA fold changes (mean ± s. d., n=3). \**p*\<0.05 vs. cells with no treatment (the 1^st^ column); ^\*\*^*p*\<0.05 vs. cells treated with AGEs alone (the 2^nd^ column); ^‡^*p*\<0.05 vs. cells treated with both AGEs and curcumin (the 3^rd^ column). (**B**) Western blotting analyses. β-tubulin was used as an internal control for equal loading. Representatives were shown from three independent experiments. *Italic* numbers beneath blots were fold changes (mean ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.](nihms352078f8){#F8}

![ERK and PPARγ acted sequentially in the attenuation of the effect of AGEs on the regulation of the expression of AGE-R1 in HSCs\
(**A**) Passaged HSCs in six-well plates were co-transfected with a total of 4.5 μg of a DNA mixture per well, including 2 μg of the promoter activity luciferase reporter plasmid pAGE-R1-Luc, 0.5μg of pSV-β-gal and 2 μg of the cDNA expression plasmid pa-ERK, encoding constitutively active ERK, at indicated doses plus the empty vector pcDNA. The latter was used to ensure an equal amount of total DNA in transfection assays. After overnight recovery, cells were serum-starved for 4 hr prior to the treatment w/wt AGEs (100 μg/ml) in the presence or absence of the PPARγ agonist PGJ~2~ (5 μM) in serum-depleted media for additional 24 hr. Luciferase activity assays were conducted (n=6). \**p*\<0.05 vs. cells with no treatment (the 1^st^ column); ^‡^*p*\<0.05 vs. cells treated with AGEs alone (the 2^nd^ column); ^§^*p*\<0.05 vs. cells transfected with no pa-ERK, but treated with both AGEs and PGJ~2~ (the 4^th^ column). The floating schema denoted pAGE-R1-Luc in use w/wt pa-ERK for co-transfection and the application of AGEs w/wt PGJ~2~ to the system.\
(B) serum-starved HSCs were treated with AGEs (100 μg/ml) and the PPARγ agonist PGJ~2~ (5 μM) plus or minus the ERK selective inhibitor PD98059 (10 μM) in serum-depleted media for 24 hr. Western blotting analyses were conducted. β-tubulin was used as an internal control for equal loading. Representatives were from three independent experiments. *Italic* numbers beneath blots were fold changes (mean ± s. d., n=3) in the densities of the bands compared with the control without treatment in the blot, after normalization with the internal invariable control.](nihms352078f9){#F9}

![A simplified action model of AGEs and curcumin in regulating the activation of HSCs\
AGEs stimulated HSC activation, which was eliminated by curcumin by inducing expression of AGE-R1 gene. The process was likely mediated by inhibiting ERK activity, inducing gene expression of PPARγ and sequentially stimulating its *trans*-activity. "↑" or "↓" indicates the effect of AGEs.](nihms352078f10){#F10}
